PCOS Has a New Name: What PMOS Means for Patients and Care

In this article, you will find a plain-language breakdown of the PCOS name change, why your diagnosis and care will stay the same, and what the shift could mean for fertility treatment and research, from a reproductive endocrinologist who specializes in the condition.

In this article:

• What PMOS Stands For
• Why the Old Name Was a Problem
• What Led to the Name Change?
• PCOS vs. PMOS: What is the Difference?
• The Three-Year Rollout Timeline
• Will My PCOS Treatment Plan Change?
• What This Means for Research and Funding
• The Emotional Impact of This Change
• Addressing Confusion & Concerns
• What PCOS Advocates Are Saying
• What to Do Next
• Frequently Asked Questions

If you have polycystic ovary syndrome, or suspect you might, you have probably seen the news. On May 12, 2026, a coalition of 56 patient and professional organizations, including the Endocrine Society and the International Androgen Excess and PCOS Society, formally announced a new name for the condition.

PCOS is now polyendocrine metabolic ovarian syndrome, or PMOS for short. As a reproductive endocrinologist who has cared for patients with this condition for over a decade, I think the renaming was overdue. Not because the science of the condition has changed, but because the language we use to describe it finally matches what we actually know about it.

Here’s what the PCOS name change means, what will stay the same, and what patients can expect as PMOS terminology rolls out over the next few years.

What PMOS Stands For

PMOS, or polyendocrine metabolic ovarian syndrome, is the new name for PCOS, or polycystic ovary syndrome. The Endocrine Society, one of the organizations behind the change, notes that the condition affects roughly one in eight women worldwide, or more than 170 million people of reproductive age.

The new name was chosen to better reflect the full hormonal and metabolic picture. And to understand why this mattered enough to change it, it helps to first look at where the old name came from.

Why the Old Name Was a Problem

Polycystic ovary syndrome was first described in 1935, when researchers believed the condition originated in the ovaries.

What look like small cysts on an ultrasound, however, are normal physiologic structures of the ovaries. These structures are called follicles; they are small, fluid-filled sacs that each contain an immature egg. They do not cause pain, they do not need to be surgically removed, and they are not the actual driver of the condition.

The real driver is hormonal. People with this condition often have elevated androgens (sometimes called male sex hormones, although everyone produces them), along with insulin resistance and disruptions in other endocrine signals.

Those imbalances affect far more than the ovaries. They influence weight regulation, blood sugar, skin and hair, mood, and long-term cardiovascular and metabolic risk.

What Led to the Name Change?

When the name leads with "cysts," patients and even some clinicians end up focused on a single feature that is not the most clinically important part of the picture.

Patients have told me for years that they felt dismissed when their concerns went beyond fertility, or that they were not screened for the metabolic risks that come with this condition. This concern has also shown up in global patient and clinician research.

A global survey of 7,708 patients and clinicians found that 86 percent of patients and 76 percent of health professionals supported a name change, citing delayed diagnoses and incomplete care as central problems.

Understanding the New Name for PCOS

Let's break down each part of the new name, polyendocrine metabolic ovarian syndrome, and why these terms are included:

• Polyendocrine means this is a hormonal condition, and that multiple endocrine systems are involved, not just one. That includes insulin, androgens, and the signals between the brain and the ovaries.
• Metabolic makes it clear that the condition carries real metabolic implications, including higher risk of type 2 diabetes, cardiovascular disease, and fatty liver. These are not side effects. They are part of the condition and need to be screened for and managed proactively.
• Ovarian keeps the connection to the reproductive system, which is still part of the clinical picture and matters for fertility, menstrual regularity, and pregnancy planning.
• Syndrome acknowledges that this is a collection of features rather than a single defined disease.

The name change is a result of 14 years of work led by Professor Helena Teede at Monash University in Australia, in partnership with patients and clinicians across six continents. The lead researchers have called it the largest medical renaming effort ever undertaken.

PCOS vs. PMOS: What Is the Difference?

It is important to be clear about the scope of this change, because the headlines can make it sound bigger than it is. The name may have changed, but the condition did not. If you were diagnosed with PCOS last year, you simply have PMOS now. Nothing about your body, your diagnosis, or your risk profile is different than it was last week.

What did change is the framing. PCOS pointed at the ovaries and the cysts that are not really cysts. PMOS points at the hormonal and metabolic systems that drive the condition.

For patients, that reframing should mean more complete screening and fewer concerns being waved off as unrelated. For the medical field, it should mean the condition is understood and studied as what it actually is.

The diagnostic criteria are the same. The treatment options are the same. The research that has been done over the past several decades still applies. This is a relabeling, and a meaningful one, but it is not a reset.

The Three-Year Rollout Timeline

The transition from PCOS to PMOS is intentional and gradual, structured around three years of education and adoption. During this transition, seeing PCOS and PMOS used side by side is normal. Some clinics, electronic health records, lab reports, and patient education materials will update quickly. Others will take longer. 

International medical societies, professional journals, and patient advocacy groups are already incorporating the new terminology, and major awareness campaigns, including multilingual patient materials, are launching alongside the announcement.

The formal endpoint is 2028. That year, the International Guideline for the assessment and management of the condition, currently used across 195 countries, will be fully updated to use PMOS.

The International Classification of Diseases (the system used to code diagnoses in medical records and insurance billing around the world) is expected to follow suit, though formal engagement with the World Health Organization on ICD coding is still in progress. That means existing coding and billing systems have not changed yet, and PCOS will remain the coded diagnosis on insurance claims and medical records until the WHO process is complete.

Key takeaway: If you are a current patient, you do not need to do anything.

Over time, you will notice the language shift on medical paperwork, PCOS-related resources, and your conversations with us. We will aim to use both names during the transition so you always know what we are referring to.

Feeling overwhelmed?

Our free workbook helps you track symptoms, prepare for appointments, and understand the full picture of this condition, from hormones to metabolism to mental health.

Will My PCOS Treatment Plan Change?

In short, no. The name may be changing, but the medicine is not. Care for PMOS, as for PCOS before it, must be individualized to your symptoms, goals, and overall health.

Depending on what you are dealing with, that care might include hormonal birth control to regulate cycles and manage androgen symptoms, insulin-sensitizing medications like metformin when there is evidence of insulin resistance, lifestyle support around nutrition and movement, mental health resources, and fertility treatment when you are ready to build a family.

For patients trying to conceive, the diagnostic criteria for PMOS in the fertility setting remain the same as they were for PCOS. We look for the following signs:

1. Irregular ovulation
2. Elevated androgens (either on blood work or based on clinical signs like acne or hair growth patterns)
3. The characteristic ovarian appearance on ultrasound or an elevated anti-Müllerian hormone (AMH) level

Note: For adolescents, only the first two criteria are required.

The framing around treatment is where I hope the new name makes the biggest difference.

PCOS care has often centered on fertility at the expense of the metabolic and mental health pieces. PMOS, as a name and as a clinical concept, will hopefully make it harder to overlook the rest of the picture. Because patients deserve screening and support across all the systems this condition touches, not just the ones tied to family building.

What This Means for Research & Funding

This change also affects how research gets funded and how the condition is positioned in medical education. The way a condition is named can influence which specialists study it, how clinicians are trained, and which research projects receive funding. PCOS has historically been underfunded relative to its prevalence, which is striking when you consider that it affects more than 170 million people of reproductive age worldwide.

The new name reframes this as an endocrine and metabolic condition, which opens doors for funding and research across a wider range of specialties. Endocrinology, cardiology, metabolic medicine, mental health research, and reproductive medicine all have a clearer stake in PMOS than they did in PCOS. The renaming team has explicitly cited expanded research funding as one of the long-term goals of this work.

For patients, that matters. More research means better screening tools, better treatments, and a deeper understanding of why this condition develops in the first place, which is still an active area of investigation.

The Emotional Impact of This Change

For some of you, seeing a diagnosis you have lived with for years suddenly shifting to a new name can feel disorienting. I want to acknowledge that. Many of our patients have done significant work to understand this condition, build community with others who share it, and advocate for themselves in medical settings. None of that work goes away.

If anything, this change is a validation of what patients have been saying for a long time. That this condition is more than a fertility issue. That it touches metabolic, hormonal, and mental health systems that have often been overlooked. That it deserves dedicated, focused, inclusive, integrated care.

Rachel Morman, who chairs Verity (the PCOS UK organization) and served on the global panel that developed the new name, put it this way: the new name "leads with hormones and recognizes the metabolic dimension of the condition."

That is the shift. The medical world's understanding of it is just finally catching up.

Addressing Confusion & Concerns

Since the announcement, some posts online have framed the name change as evidence that cysts "aren't real." That is not the case, and I understand why it may feel dismissive.

Ovarian cysts are real, and some patients do have them. Functional cysts, dermoid cysts, endometriomas, and other types can develop in the ovaries and sometimes rupture, cause pain, or lead to other complications that need medical attention. Those are real diagnoses with existing treatment paths.

What the renaming is addressing is something different. The small, fluid-filled structures seen on ultrasound in patients with this condition are follicles, not pathological cysts, and they are not the underlying driver of the syndrome. A patient with PMOS can also separately develop an ovarian cyst, and if that happens, it is treated as its own issue.

The renaming is not erasing cysts as a medical reality. It is moving them out of the center of how this particular condition is defined, because the hormonal and metabolic features are what actually shape the diagnosis and the treatment plan.

What PCOS Advocates Are Saying About the Name Change

It's important to acknowledge that not everyone in the PCOS community is in favor of the renaming. Some long-time advocates have voiced concerns, particularly around losing the recognition and visibility that the PCOS name has built up over decades, and around what that means for the patients, organizations, and resources tied to it.

Those are fair concerns. A name carries history, community, and a body of awareness work that took years to create. The renaming team has acknowledged this and built the multi-year rollout plan in part to address it, with both names remaining in use during the transition so the existing awareness infrastructure is not severed overnight.

Whether the new name ultimately strengthens or fragments the community is something we will only know with time, and the patients who have done the work of building PCOS visibility deserve a seat at that table as it unfolds.

What to Do Next

If you are a patient at Illume Fertility and want to talk through what this means for you, please reach out to your Care Team. If you are not yet a patient but you suspect you might have PMOS, the most useful next step is fertility testing and a hormonal workup, which can be discussed at an initial consultation.

You can learn more about our PCOS program (the name on our materials will be updated over the course of the transition period) or schedule a consultation through our website.

It took 14 years and the voices of more than 22,000 patients and health professionals to get here. To everyone in the PCOS community who have been advocating tirelessly for increased awareness and better care, thank you. The rest of us are paying attention.

PCOS Care, Tailored to You

Our PCOS program brings together reproductive endocrinology, nutrition, mental health support, and metabolic screening under one roof.

Frequently Asked Questions

Quick answers to potential questions about the name change:

Is PCOS now PMOS?

Yes. The renaming became official on May 12, 2026, when polycystic ovary syndrome was formally changed to polyendocrine metabolic ovarian syndrome. Both names will be in circulation throughout the three-year transition from PCOS to PMOS, and you can expect to see both terms referenced interchangeably during this time.

Why did PCOS get renamed?

The previous name put the emphasis on ovarian cysts, which are not pathological cysts and not actual drivers of the condition. PMOS was chosen to capture the hormonal and metabolic reality that patients and researchers have pointed to for years.

Does PMOS mean I no longer have PCOS?

No. Your diagnosis has not changed. PCOS and PMOS describe the exact same condition, so a past PCOS diagnosis carries forward as PMOS with no clinical differences.

Can PMOS affect fertility?

Yes. Because PMOS can disrupt ovulation and menstrual cycles, it is relevant to family building, and effective fertility treatment options exist for many patients.

Does PMOS mean ovarian cysts are not involved?

What shows up on an ultrasound are follicles, a normal part of the ovary, rather than pathological cysts. Part of the reason for the new name is to move attention away from those structures and toward the hormonal and metabolic features that actually define the condition.

When will doctors start using PMOS instead of PCOS?

The shift is expected to take roughly three years, with full adoption tied to the 2028 updates to the International Guideline and the International Classification of Diseases. Some clinics and organizations have already started using the new term.